Genentech, Inc.
Two Phase III Studies of Lucentis Show Early and Sustained Improvement in Vision in Patients with Retinal Vein Occlusion
Published in Pharma Investments, Ventures and Law Weekly, October 25th, 2009
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced results from two Phase III studies of Lucentis® (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented today at the Retina Congress 2009 meeting.
Data from the BRAVO study in branch-RVO showed at month...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- 40 Days for Life
New Chicago Ordinance Targets 40 Days for Life, Tramples Pro-Life Americans' Free Speech Rights - AARP Pennsylvania
AARP Pennsylvania Applauds U.S. Rep. Altmire's Floor Speech Supporting Older Driver Safety Bill - Acacia Research Corporation
Acacia Subsidiary Enters into License Agreement with Valpak - ACLJ
ACLJ: Supreme Court Must Uphold Cross Display in CA's Mojave Desert - ADT Security Services
ADT Safety Tips: Parking Lot Safety - Advanced Analogic Technologies, Inc.
AnalogicTech Comments on Recent Developments in Patent Litigation - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
